2023 TreeFrog’s wishes


110+ Froggies across France, USA and Japan wish you a Merry Christmas and all the best for 2023 !

What happened in 2022 at TreeFrog?

Moving to GMP manufacturing

2 years ago, we announced we would have a GMP-grade encapsulation device by the end of 2022. Here we are ! Right on time!

First collaboration in  immuno-oncology 

This collaboraion with US-based biotech Umoja Biopharma aims at leveraging the C-Stem™ platform for the large-scale amplification and immune differentiation of Umoja’s iPS cell line edited with the RACR™ technology.

$100,000 to 3 PhD students from King’s College London

In October, we were glad to award the $100,000 Stem Cell SpaceShot Grant to a team working on the reprogramming of iPS-derived macrophages for neuronal repair.

3 new independent board members

We added industry insiders to our Board in 2022: Elsy Boglioli, Chair of the Board (formerly Cellectis), Melissa Carpenter, PhD (Elevate Bio) and Peter Nell, PhD (formerly Bayer, Mammoth Biosciences, Casebia).

Word-class scientific advisors in physics, stem cells & gene editing

In March 2022, TreeFrog announced the formation of its scientific advisory board, with a strong bias for interdisciplinarity. 


Opening hubs in Kobe and Boston

In October, co-founder Kévin Alessandri moved to Boston to lead our technological hub at Lab Central 238 (Cambridge-Kendall Square, MA, USA). In Japan, our team is currently setting up the lab at the Creative Lab for Innovation in Kobe (CLIK). 
Why hubs ? To showcase our technology and build local partnerships. Curious? Come and visit us!

SPOILER ARLERT – What to expect in 2023 ?

In vivo results in Parkinson’s disease with cryopreserved product

In 2023, the Parkinson team will present new preclinical data, demonstrating fast and complete motor function recovery with cryopreserved neural microtissues. (We can already tell we love the pictures!)

Tech transfer of the
C-Stem™ platform

Our GMP platform will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce the first clinical-grade batches of our cell therapy candidate for Parkinson’s disease.

More to come in immuno-oncology

In addition to our collaboration with Umoja, TreeFrog has been moving forward with gene-editing, iPSC-to-embryoid body scale-up and amplification of T and NK cells in the capsule. We’ll keep you posted.

Let’s meet in 2023, in the USA, Japan or EU

We will attend over 20 scientific and business events in 2023.
. If you’re attending the ISCT meeting in Paris in May – visit us in Bordeaux!
. If you’re attending the ISSCR meeting in Boston in June – pop into our office at LabCentral 238, in Kendall Square, Cambridge.

Wishing you a very successful, healthy and happy 2023 !

Frédéric, Kévin & Maxime, and the Froggies